Clinical Trial Update: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 safety study update for SG301-SC in systemic lupus erythematosus; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SG301-SC

Snippet

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 1 | Status: ACTIVE_NOT_RECRUITING